CH472404A - Process for the production of new indole derivatives - Google Patents
Process for the production of new indole derivativesInfo
- Publication number
- CH472404A CH472404A CH315466A CH315466A CH472404A CH 472404 A CH472404 A CH 472404A CH 315466 A CH315466 A CH 315466A CH 315466 A CH315466 A CH 315466A CH 472404 A CH472404 A CH 472404A
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- reaction
- acid
- methyl
- epichlorohydrin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 12
- 229940054051 antipsychotic indole derivative Drugs 0.000 title claims description 3
- 150000002475 indoles Chemical class 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- NLMQHXUGJIAKTH-UHFFFAOYSA-N 4-hydroxyindole Chemical class OC1=CC=CC2=C1C=CN2 NLMQHXUGJIAKTH-UHFFFAOYSA-N 0.000 claims description 6
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- -1 potassium carbonate Chemical class 0.000 description 4
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LJFVSIDBFJPKLD-UHFFFAOYSA-N 4-phenylmethoxy-1h-indole Chemical compound C=1C=CC=2NC=CC=2C=1OCC1=CC=CC=C1 LJFVSIDBFJPKLD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NXWGWUVGUSFQJC-UHFFFAOYSA-N mepindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- FGGWBXKCGYCYGV-UHFFFAOYSA-N 1-(1-methylindol-4-yl)oxy-3-(propan-2-ylamino)propan-2-ol Chemical compound C(C)(C)NCC(COC1=C2C=CN(C2=CC=C1)C)O FGGWBXKCGYCYGV-UHFFFAOYSA-N 0.000 description 1
- YIUIPTVCXWPNJM-UHFFFAOYSA-N 1-(butan-2-ylamino)-3-(1H-indol-4-yloxy)propan-2-ol Chemical compound CCC(C)NCC(COC1=CC=CC2=C1C=CN2)O YIUIPTVCXWPNJM-UHFFFAOYSA-N 0.000 description 1
- AADKPSZXBUUSOX-UHFFFAOYSA-N 1-(cyclopropylamino)-3-(1H-indol-4-yloxy)propan-2-ol Chemical compound OC(COC1=C2C=CNC2=CC=C1)CNC1CC1 AADKPSZXBUUSOX-UHFFFAOYSA-N 0.000 description 1
- QMHJCIVEEBUCFP-UHFFFAOYSA-N 1-[(3-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C(C)=CN2 QMHJCIVEEBUCFP-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- PXYRYFLSOOBYGT-UHFFFAOYSA-N 2-(4-phenylmethoxy-1H-indol-2-yl)acetonitrile Chemical compound C(C1=CC=CC=C1)OC1=C2C=C(NC2=CC=C1)CC#N PXYRYFLSOOBYGT-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- BGQHPLYSXBZMQG-UHFFFAOYSA-N 4-(2-Hydroxy-3-tert-butylaminopropoxy)-2-methylindole Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(O)CNC(C)(C)C BGQHPLYSXBZMQG-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- WUCPCORZZJWVHG-UHFFFAOYSA-N 4-bromo-2-propylthiophene Chemical compound CCCC1=CC(Br)=CS1 WUCPCORZZJWVHG-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical class C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000000323 adipokinetic effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001834 epinephrinelike Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- LYBKPDDZTNUNNM-UHFFFAOYSA-N isopropylbenzylamine Chemical compound CC(C)NCC1=CC=CC=C1 LYBKPDDZTNUNNM-UHFFFAOYSA-N 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007530 organic bases Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Verfahren zur Herstellung neuer lidolderivate
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung neuer Indolderivate der Formel I,
EMI1.1
worin Rl Wasserstoff oder Methyl bedeutet und R2 für die Isopropyl-, Cyclopropyl-, sek. Butyl oder tert.-Butylgruppe steht, und ihrer Säureadditionssalze. Wenn R eine Methylgruppe bedeutet, kann diese in 1-, 2- oder 3-Stellung des Indolgerüstes sitzen.
Die Verbindungen der Formel I sind in der Literatur bisher nicht beschrieben worden; sie zeichnen sich bei geringer Toxizität durch interessante pharmakodynamische Eigenschaften aus. Insbesondere besitzen sie eine ausgeprägte, lang anhaltende bradykarde und eine gewisse blutdrucksenkende Wirkung. Sie beeinflussen Adrenalineffekte am Blutdruck nicht, hemmen aber die durch Adrenalin erzeugte Tachykardie. Die Verbindungen entfalten eine Hemmwirkung gegenüber Kreislaufeffekten des Isoprenalins [1 -(3 4-Dihydroxyphenyl)-2-isopropyl- aminoäthanol] und besitzen demnach eine Blockerwirkung auf die-Rezeptoren des adrenergischen Nervensystems.
In entsprechender Dosierung besitzen sie auch x-Re- zeptorenerregende Aktivität sowie adipokinetische und glukokinetische Eigenschaften (d.h. sie beeinflussen den Transport von Lipoiden bzw. I Kohlehydraten im Orga- nismus).
Die obgenannten Eigenschaften treten insbesondere beim 2-Methyl-4-(2-hydroxy-3-isopropylaminopropoxy)- -indol und beim 4-(2-Hydroxy-3-isopropylaminopropoxy) -indol hervor. Die neuen Verbindungen sind bekannten Präparaten ähnlicher Wirkungsrichtung eindeutig überlegen.
Die Verbindungen können als Heilmittel verwendet werden, insbesondere zur Prophylaxe oder Behandlung von Coronarerkrankungen und anginösen Beschwerden, zur Behandlung von Herzarrhythmien und Rhythmusstörungen, die mit einer Tachykardie einhergehen, sowie zur Therapie der Hypertonie.
Das Verfahren gemäss vorliegender Erfindung ist dadurch gekennzeichnet, dass man Epichlorhydrin mit Aminen der Formel II
EMI1.2
umsetzt, die Reaktionsprodukte in alkalischer Lösung und unter Sauerstoffausschluss mit Hydroxyindolen der Formel III
EMI1.3
kondensiert, hierauf die Benzylgruppe hydrogenolytisch abspaltet und gegebenenfalls die erhaltenen Verbindungen durch Umsetzung mit anorganischen oder organischen Säuren in die entsprechenden Salze überführt.
Das erfindungsgemässe Verfahren wird im folgenden näher erläutert:
Die Umsetzung von Epichlorhydrin mit dem Amin der Formel II erfolgt durch Erwärmen der Komponenten, vorzugsweise in einem inerten Lösungsmittel, wie Benzol oder Toluol. Die Temperatur beträgt ca. 50- 1100, die Reaktionszeit 1 bis mehrere Stunden. Der Zusatz eines säurebindenden Mittels, z.B. einer tertiären organischen Base, wie Pyridin oder Triäthylamin, oder einer anorganischen Base, wie Kaliumcarbonat, kann vorteilhaft sein. ist jedoch nicht notwendig.
Zur Umsetzung mit dem oben erhaltenen Reaktionsprodukt wird das Hydroxyindol der Formel III vorzugsweise in Form eines Alkali- oder Ammoniumsalzes eingesetzt. Hierzu löst man es in einer äquimolaren alkoholischen oder vorzugsweise wässrigen Alkalihydroxydoder Ammoniaklösung, versetzt mit 1 bis 3 Äquivalen ten des vorerwähnten Zwischenproduktes und rührt das Gemisch während mehrerer Stunden bei 20-500.
Nach einer Variante des Verfahrens verdampft man eine alkoholische Lösung des Alkalisalzes des l : Hydroxy- indols der Formel III zur Trockne und suspendiert den Rückstand in Dimethoxyäthan oder man setzt das Hydroxyindol der Formel III in einem inerten organischen Lösungsmittel, wie Benzol, Toluol usw., mit der äquimolaren Menge eines Alkalimetallalkoholates, -amides oder -hydrides um; anschliessend gibt man - wie oben 1 bis 3 Äquivalente des Reaktionsproduktes von Epichlorhydrin mit dem Amin II zu und rührt das Gemisch während mehrerer Stunden bei 20 - 500.
Hydroxy-indole sind in alkalischer Lösung äusserst oxydationsempfindlich; die vorstehend beschriebenen Massnahmen erfolgen daher unter Sauerstoffausschluss, z.B. in einer Stickstoffatmosphäre. Die Entfernung der Benzylgruppe erfolgt durch Behandlung mit katalytisch erregtem Wasserstoff, vorzugsweise in einem niederen Alkanol in Gegenwart eines Palladium-Katalysators.
Die Endprodukte des Verfahrens können als freie Basen oder in Form ihrer Salze nach bekannten Methoden isoliert und gereinigt werden. Sie stellen farblose, meist kristalline Stoffe dar, die in Wasser wenig, in organischen Lösungsmitteln meist gut löslich sind. Mit dem Keller-Reagens (Eisen-III-chlorid enthaltender Eisessig und konz. Schwefelsäure) und dem Van Urk-Reagens (p-Dimethylaminobenzaldehyd und verd. Schwefelsäure) geben sie im allgemeinen charakteristische Färbungen.
Die Erfindung umfasst auch die Herstellung von Säureadditionssalzen der neuen Verbindungen, z.B. mit anorganischen Säuren, wie Chlorwasserstoff, Bromwasserstoff oder Schwefelsäure, oder mit organischen Säuren, wie Fumarsäure, Maleinsäure, Weinsäure, Benzoesäure, Methan-, Äthan- oder p-Toluolsulfonsäure usw. 4-Hydroxyindol ist bekannt. Derivate, die im Pyrrolring eine Methylgruppe tragen, können beispielsweise folgendermassen erhalten werden:
1. Methylgruppe in 1-Stellung: Man methyliert 4 -Benzyloxyindol, beispielsweise durch Umsetzung mit Methyljodid in flüssigem Ammoniak unter Zusatz von Natriumamid, und spaltet anschliessend die Benzylgruppe hydrogenolytisch ab, z.B. durch Schütteln mit Palladium und Wasserstoff in Methanol.
2. Methylgruppe in 3-Stellung: Man führt 4-Benzyloxyindol mit Formaldehyd und Dimethylamin in schwach saurer Lösung in das entsprechende Benzyloxygramin über und hydriert dieses über Palladium in Methanol, wobei gleichzeitig Abspaltung der Dimethylamino- und der Benzylgruppe erfolgen.
3. Methylgruppe in 2-Stellung: Man führt 4-Benzyloxyindol-2-carbonsäure über das Säurechlorid in das Dimethylamid über, reduziert dieses mit Lithiumaluminiumhydrid zum entsprechenden Dimethylamin. das man mit einem Methylhalogenid quartärisiert. Durch Erhitzen mit wässriger Natriumcyanidlösung gewinnt man hieraus 2-Cyanomethyl-4-benzyloxyindol. hydrolysiert dieses und decarboxyliert die erhaltene Säure; die Benzylgruppe wird hydrogenolytisch abgespalten.
Im nachfolgenden Beispiel erfolgen alle Temperaturangaben in Celsiusgraden, ohne Korrekturen.
Beispiel 4-(-Hydroxy-3-isoprnpy[atiinoprnpoxy)üidol
Man erhitzt ein Gemisch von 18,4 g Epichlorhydrin und 29,8 g N-Benzylisopropylamin in 100 ml Benzol 24 Stunden am Rückfluss zum Sieden, verdampft hierauf das Lösungsmittel und destilliert den Rückstand im Hochvakuum; Sdp. 107- 1100/0,03 mm mm Hg.
14,6 g dieses Destillats gibt man zu einer mit Stickstoff bespülten Lösung von 7,3 g 4-Hydroxyindol und 2,25 g Natriumhydroxyd in 50 ml Wasser. Man rührt 24 Stunden bei 4(je, extrahiert das Reaktionsgemisch 4 mal mit Methylenchlorid und dampft die vereinigten, über Magnesiumsulfat getrockneten organischen Schichten unter vermindertem Druck ein. Man schüttelt den Rückstand 3 mal zwischen Essigester und 1 N Weinsäurelösung aus und versetzt hierauf die vereinigten weinsauren Phasen bis zur alkalischen Reaktion mit Natronlauge. Man schüttelt mit Essigester aus, trocknet die organische Phase über Pottasche, versetzt sie mit 1 g eines Palladiumkatalysators (5% auf Sohle) und schüttelt mit Wasserstoff bis zum Stillstand der Aufnahme.
Der Katalysator wird abfiltriert, das Filtrat zur Trockne eingedampft und der Rückstand aus Äthanol umkristal ligiert, wobei man die im Titel genannte Verbindung vom Smp. 171 - 1730 (Nadeln) erhält.
Keller'sche Farbreaktion (0,2 mg): olivgrün
Van Urk'sche Farbreaktion (1 mg): vor Belichtung lila, nachher dunkel lila-violett.
Nach demselben Verfahren können auch folgende Verbindungen hergestellt werden: 1 -Methyl-4-(2-hydroxy-3 -isopropylaminopropoxy)indol Smp. 79 - 810 (aus Essigester/Äther); 3-Methyl-4-(2-hydroxy-3-isopropylaminopropoxy)indol Smp. 95- 970 (aus Benzol/Ligroin); 4-(2-Hydroxy-3 -cyclopropylaminopropoxy)indol Smp. 118 - 1200 (Nadeldrusen aus Essigester); 4-(2-Hydroxy-3-sek.butylaminopropoxy)indol Smp. 154 - 1560 (Prismen aus Methanol /Essigester); 2-Methyl-4-(2-hydroxy-3-isopropylaminopropoxy)indol Smp. 95 - 970 (aus Essigester); 2-Methyl-4-(2-hydroxy-3 -tert.butylaminopropoxy)indol Smp. 131 - 1330 (aus Essigester).
Process for the production of new lidol derivatives
The present invention relates to a process for the preparation of new indole derivatives of the formula I,
EMI1.1
where Rl is hydrogen or methyl and R2 is the isopropyl, cyclopropyl, sec. Butyl or tert-butyl group, and their acid addition salts. If R is a methyl group, this can be in the 1-, 2- or 3-position of the indole structure.
The compounds of the formula I have not yet been described in the literature; they are characterized by interesting pharmacodynamic properties with low toxicity. In particular, they have a pronounced, long-lasting bradycardia and a certain antihypertensive effect. They do not influence the adrenaline effects on blood pressure, but inhibit the tachycardia produced by adrenaline. The compounds have an inhibitory effect on the circulatory effects of isoprenaline [1- (3 4-dihydroxyphenyl) -2-isopropylaminoethanol] and accordingly have a blocking effect on the receptors of the adrenergic nervous system.
In appropriate doses, they also have x-receptor-stimulating activity as well as adipokinetic and glucokinetic properties (i.e. they influence the transport of lipoids or I carbohydrates in the organism).
The properties mentioned above are particularly evident in the case of 2-methyl-4- (2-hydroxy-3-isopropylaminopropoxy) indole and 4- (2-hydroxy-3-isopropylaminopropoxy) indole. The new compounds are clearly superior to known preparations with a similar direction of action.
The compounds can be used as medicaments, in particular for the prophylaxis or treatment of coronary diseases and anginal complaints, for the treatment of cardiac arrhythmias and arrhythmias associated with tachycardia, and for the therapy of hypertension.
The method according to the present invention is characterized in that epichlorohydrin with amines of the formula II
EMI1.2
converts the reaction products in alkaline solution and with exclusion of oxygen with hydroxyindoles of the formula III
EMI1.3
condensed, then the benzyl group is split off hydrogenolytically and, if appropriate, the compounds obtained are converted into the corresponding salts by reaction with inorganic or organic acids.
The method according to the invention is explained in more detail below:
The reaction of epichlorohydrin with the amine of the formula II is carried out by heating the components, preferably in an inert solvent such as benzene or toluene. The temperature is approx. 50-1100, the reaction time 1 to several hours. The addition of an acid binding agent, e.g. a tertiary organic base such as pyridine or triethylamine, or an inorganic base such as potassium carbonate, can be advantageous. however, it is not necessary.
For the reaction with the reaction product obtained above, the hydroxyindole of the formula III is preferably used in the form of an alkali or ammonium salt. To do this, it is dissolved in an equimolar alcoholic or preferably aqueous alkali metal hydroxide or ammonia solution, mixed with 1 to 3 equivalents of the above-mentioned intermediate and the mixture is stirred for several hours at 20-500.
According to a variant of the process, an alcoholic solution of the alkali metal salt of the l: hydroxyindole of the formula III is evaporated to dryness and the residue is suspended in dimethoxyethane or the hydroxyindole of the formula III is placed in an inert organic solvent such as benzene, toluene, etc. with the equimolar amount of an alkali metal alcoholate, amide or hydride; then - as above - 1 to 3 equivalents of the reaction product of epichlorohydrin with the amine II are added and the mixture is stirred for several hours at 20-500.
Hydroxyindoles are extremely sensitive to oxidation in alkaline solutions; the measures described above are therefore carried out with the exclusion of oxygen, e.g. in a nitrogen atmosphere. The benzyl group is removed by treatment with catalytically excited hydrogen, preferably in a lower alkanol in the presence of a palladium catalyst.
The end products of the process can be isolated and purified as free bases or in the form of their salts by known methods. They are colorless, mostly crystalline substances that are only slightly soluble in water and mostly well soluble in organic solvents. With the Keller reagent (glacial acetic acid and conc. Sulfuric acid containing ferric chloride) and the Van Urk reagent (p-dimethylaminobenzaldehyde and dilute sulfuric acid) they generally give characteristic colors.
The invention also encompasses the preparation of acid addition salts of the new compounds, e.g. with inorganic acids such as hydrogen chloride, hydrogen bromide or sulfuric acid, or with organic acids such as fumaric acid, maleic acid, tartaric acid, benzoic acid, methane, ethane or p-toluenesulphonic acid etc. 4-hydroxyindole is known. Derivatives which have a methyl group in the pyrrole ring can be obtained, for example, as follows:
1. Methyl group in position 1: 4 -benzyloxyindole is methylated, for example by reaction with methyl iodide in liquid ammonia with the addition of sodium amide, and the benzyl group is then split off hydrogenolytically, e.g. by shaking with palladium and hydrogen in methanol.
2. Methyl group in position 3: 4-Benzyloxyindole is converted into the corresponding benzyloxygramine with formaldehyde and dimethylamine in weakly acidic solution and this is hydrogenated over palladium in methanol, the dimethylamino and benzyl groups being split off at the same time.
3. Methyl group in position 2: 4-Benzyloxyindole-2-carboxylic acid is converted into dimethylamide via the acid chloride, and this is reduced with lithium aluminum hydride to give the corresponding dimethylamine. which is quaternized with a methyl halide. 2-Cyanomethyl-4-benzyloxyindole is obtained from this by heating with aqueous sodium cyanide solution. hydrolyzes this and decarboxylates the acid obtained; the benzyl group is split off by hydrogenolysis.
In the following example all temperatures are given in degrees Celsius, without corrections.
Example 4 - (- Hydroxy-3-isoprnpy [atiinoprnpoxy) idol
A mixture of 18.4 g of epichlorohydrin and 29.8 g of N-benzylisopropylamine in 100 ml of benzene is refluxed for 24 hours, the solvent is then evaporated and the residue is distilled in a high vacuum; Bp. 107-1100 / 0.03 mm mm Hg.
14.6 g of this distillate are added to a nitrogen-flushed solution of 7.3 g of 4-hydroxyindole and 2.25 g of sodium hydroxide in 50 ml of water. The mixture is stirred for 24 hours at 4 (each time, the reaction mixture is extracted 4 times with methylene chloride and the combined organic layers, dried over magnesium sulfate, are evaporated under reduced pressure. The residue is shaken 3 times between ethyl acetate and 1N tartaric acid solution, and the combined tartaric acids are then added Phases up to an alkaline reaction with sodium hydroxide solution: Shake out with ethyl acetate, dry the organic phase over potash, add 1 g of a palladium catalyst (5% on sole) and shake with hydrogen until absorption stops.
The catalyst is filtered off, the filtrate is evaporated to dryness and the residue is ligated recrystallized from ethanol, giving the compound named in the title with a melting point of 171-1730 (needles).
Keller's color reaction (0.2 mg): olive green
Van Urk's color reaction (1 mg): before exposure purple, afterwards dark purple-purple.
The following compounds can also be prepared by the same process: 1-methyl-4- (2-hydroxy-3-isopropylaminopropoxy) indole mp 79-810 (from ethyl acetate / ether); 3-methyl-4- (2-hydroxy-3-isopropylaminopropoxy) indole m.p. 95-970 (from benzene / ligroin); 4- (2-hydroxy-3-cyclopropylaminopropoxy) indole m.p. 118-1200 (needle drums from ethyl acetate); 4- (2-hydroxy-3-sec-butylaminopropoxy) indole mp 154-1560 (prisms from methanol / ethyl acetate); 2-methyl-4- (2-hydroxy-3-isopropylaminopropoxy) indole m.p. 95-970 (from ethyl acetate); 2-methyl-4- (2-hydroxy-3-tert-butylaminopropoxy) indole. Mp. 131-1330 (from ethyl acetate).
Claims (1)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH315466A CH472404A (en) | 1966-03-04 | 1966-03-04 | Process for the production of new indole derivatives |
| ES337457A ES337457A1 (en) | 1966-03-04 | 1967-03-02 | PROCEDURE FOR THE PRODUCTION OF INDOLIC DERIVATIVES. |
| FI61667A FI47365C (en) | 1966-03-04 | 1967-03-02 | Process for the preparation of new therapeutically active indolder t. |
| CS155667A CS156406B2 (en) | 1966-03-04 | 1967-03-02 | |
| DK112867A DK121168B (en) | 1966-03-04 | 1967-03-03 | Process for the preparation of indole derivatives. |
| SE293067A SE308720B (en) | 1966-03-04 | 1967-03-03 | |
| AT205967A AT266112B (en) | 1966-03-04 | 1967-03-03 | Process for the production of new indole derivatives and their salts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH315466A CH472404A (en) | 1966-03-04 | 1966-03-04 | Process for the production of new indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH472404A true CH472404A (en) | 1969-05-15 |
Family
ID=4249777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH315466A CH472404A (en) | 1966-03-04 | 1966-03-04 | Process for the production of new indole derivatives |
Country Status (7)
| Country | Link |
|---|---|
| AT (1) | AT266112B (en) |
| CH (1) | CH472404A (en) |
| CS (1) | CS156406B2 (en) |
| DK (1) | DK121168B (en) |
| ES (1) | ES337457A1 (en) |
| FI (1) | FI47365C (en) |
| SE (1) | SE308720B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| WO2007024945A1 (en) | 2005-08-25 | 2007-03-01 | Novartis Ag | Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase |
| WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| US10251959B2 (en) | 2007-03-12 | 2019-04-09 | Nektar Therapeutics | Oligomer-beta blocker conjugates |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC1357A1 (en) * | 1979-12-07 | 1981-08-10 | Hoffmann La Roche | 2,3-INDOLEDIONE DERIVATIVES |
-
1966
- 1966-03-04 CH CH315466A patent/CH472404A/en not_active IP Right Cessation
-
1967
- 1967-03-02 FI FI61667A patent/FI47365C/en active
- 1967-03-02 ES ES337457A patent/ES337457A1/en not_active Expired
- 1967-03-02 CS CS155667A patent/CS156406B2/cs unknown
- 1967-03-03 SE SE293067A patent/SE308720B/xx unknown
- 1967-03-03 DK DK112867A patent/DK121168B/en unknown
- 1967-03-03 AT AT205967A patent/AT266112B/en active
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| WO2007024945A1 (en) | 2005-08-25 | 2007-03-01 | Novartis Ag | Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase |
| EP2256118A1 (en) | 2005-08-25 | 2010-12-01 | Novartis AG | Condensed imidazolo derivatives for the inhibition of aromatase |
| EP2270011A1 (en) | 2005-08-25 | 2011-01-05 | Novartis AG | Condensed imidazolo derivatives for the inhibition of aromatase |
| EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
| WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| US10251959B2 (en) | 2007-03-12 | 2019-04-09 | Nektar Therapeutics | Oligomer-beta blocker conjugates |
| US10881738B2 (en) | 2007-03-12 | 2021-01-05 | Nektar Therapeutics | Oligomer-beta blocker conjugates |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| EP4470609A2 (en) | 2019-01-18 | 2024-12-04 | Astrazeneca AB | Pcsk9 inhibitors and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| FI47365C (en) | 1973-11-12 |
| AT266112B (en) | 1968-11-11 |
| ES337457A1 (en) | 1968-03-01 |
| DK121168B (en) | 1971-09-20 |
| FI47365B (en) | 1973-07-31 |
| CS156406B2 (en) | 1974-07-24 |
| SE308720B (en) | 1969-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1963182A1 (en) | New N-phenylindoline derivatives and their use as drugs | |
| CH472404A (en) | Process for the production of new indole derivatives | |
| CH301670A (en) | Process for the preparation of a morphine derivative. | |
| DE934651C (en) | Process for the preparation of tetrasubstituted diaminoalkanes | |
| DE2639291C2 (en) | ||
| DE1905881A1 (en) | Process for the preparation of new heterocyclic compounds | |
| CH523884A (en) | Process for the production of new indole derivatives | |
| AT303025B (en) | PROCESS FOR THE PRODUCTION OF NEW INDOLDER DERIVATIVES AND THEIR ACID ADDITION SALTS | |
| DE1620342C3 (en) | ||
| DE745314C (en) | Process for the preparation of 1-oxyphenyl-3-aminoalkyl compounds with an analgesic effect | |
| AT250338B (en) | Process for the preparation of new, basic derivatives of substituted benzofuran-2-carboxylic acids and their salts | |
| CH473821A (en) | Process for the preparation of iminodibenzyl derivatives | |
| CH535236A (en) | 6-nor-lysergic acid derivs - with pharmacological activity | |
| CH511839A (en) | Beta-blocking indolyloxy-propanolamines | |
| AT235283B (en) | Process for the preparation of new indole compounds | |
| AT255422B (en) | Process for the preparation of new iminodibenzyl derivatives | |
| AT213885B (en) | Process for the production of new indole derivatives | |
| CH483423A (en) | Process for the preparation of a new indole compound | |
| AT221087B (en) | Process for the production of new, basic indole derivatives | |
| CH543505A (en) | 4-(3-Alkylamino-2-hydroxypropoxy) indoles - with beta-receptor blocking activity | |
| DE2345651A1 (en) | INDOLYL ALKYLAMINES AND THE PROCESS FOR THEIR PRODUCTION | |
| AT360992B (en) | METHOD FOR PRODUCING NEW PHENYLAZACYCLO-ALKANS AND THEIR SALTS AND OPTICALLY ACTIVE COMPOUNDS | |
| AT400146B (en) | Process for the preparation of 1-(2-((5-dimethylamino methyl-2-furyl)methylthio)ethyl)amino-1-methylamino-2- nitroethylene | |
| CH502337A (en) | Indole derivs - adrenergic beta blockers | |
| CH526541A (en) | 4-substd indole-2-carbaldehydes - from 4-substd 2 - methylhydroxyindole and manganese dioxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |